The Research Of MicroRNA In Peripheral Blood In Diagnosing Prostate Cancer

Objective: To demonstrate that some micro RNA having different expression in blood could be diagnostic molecular biomarker,by detecting stable expression of micro RNA.And to find new method that associated panel with clinical index and micro RNA to diagnose prostate cancer,by means of detecting discrepant expression of micro RNA and analyzing patients’ basic data such as age,prostate volume,prostatic specific antigen(PSA).Doctors could diagnose and distinguish prostate cancer(PCa)from other prostatic diseases with new method.Method:(1)Serum micro RNAs with stable different expression by means of high throughput micro RNA microarray in 72 plasma were found in PCa,benign prostatic hyperplasia(BPH)and healthy.(2)The expression level of micro RNA was detected by verification method(Taqman probe real-time fluorescent quantitative PCR)in collected serum from PCa and BPH in our hospital.The diagnostic performance and value of checked micro RNAs in clinical adhibition were verified by statistical method AUC-ROC.The Logistics regression equation of diagnosing PCa was established by uniting PSA,prostate volume,f/t,age with selected micro RNA,to find the best method of new type model for diagnosing PCa.And the combined model was verified in serum from multiple centers to examine its diagnostic value.The clinical blood samples used in the experiment were samples of patients who were not treated with any remedy associated with prostatic diseases before collecting samples.Results: 15 micro RNAs were chosen from high throughput microarray.hsa-miR-365,hsa-miR-4286,hsa-miR-42,hsa-miR-27 a and hsa-miR-29 b with discrepant expression in validation phase in 155 serum samples had potential diagnostic value.The Logistics regression equation was established by 5 parameters of PSA,prostate volume,miR-4286,miR-27 a and miR-29 b and ROC of accompanied model was made with AUC up to 0.892(95% CI:.832-0.937,sensitivity 78.95%,specificity 92.21%).The panel had excellent diagnostic performance and its significance was tested in 100 serum samples from multiple centers.Conclusions: Serum miR-4286,miR-27 a and miR-29 b were favorable new molecular biomarkers in distinguishing prostate cancer and had potential clinical application value.Better diagnostic performance was found by panel composed of PSA and prostate volume.